Precision BioSciences, Inc. Common Stock

DTIL XNAS • BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

190M

Short interest (Jul 15)

9.2%

Net Short (Jul 27 ): 0.0%

Borrow Fee

1.17%

↓ 4.8%

Available Shares

400K

↓ 47.5%

Price Chart

Company Overview

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

Company Info

Exchange: NASDAQ

Industry: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

CIK: 0001357874

Asset Type: CS

Market Data

Market Cap: $188,098,380

Employees: 66

Status: Active

Short Interest

Current Borrow Fee 1.17%

Range: 1.08% - 1.17%

Available Shares 400K

Range: 200K - 400K

Recent Changes

Fee Change: ↓ 8.7%

Available Change: ↑ 83.3%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime